2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

2seventy bio, Inc. (NASDAQ:TSVT) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $7.20.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 2seventy bio in a research note on Saturday, February 1st.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors have recently added to or reduced their stakes in TSVT. Erste Asset Management GmbH purchased a new position in shares of 2seventy bio in the 3rd quarter worth about $25,000. American Century Companies Inc. increased its position in 2seventy bio by 6.6% during the 4th quarter. American Century Companies Inc. now owns 93,552 shares of the company’s stock worth $275,000 after purchasing an additional 5,785 shares in the last quarter. Intech Investment Management LLC raised its holdings in 2seventy bio by 41.1% in the fourth quarter. Intech Investment Management LLC now owns 20,688 shares of the company’s stock valued at $61,000 after buying an additional 6,030 shares during the period. Wells Fargo & Company MN lifted its position in 2seventy bio by 23.2% during the fourth quarter. Wells Fargo & Company MN now owns 32,532 shares of the company’s stock valued at $96,000 after buying an additional 6,133 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in 2seventy bio by 9.5% during the fourth quarter. Rhumbline Advisers now owns 84,670 shares of the company’s stock valued at $249,000 after buying an additional 7,379 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Trading Up 2.6 %

2seventy bio stock opened at $2.39 on Thursday. The stock has a fifty day moving average price of $2.83 and a 200 day moving average price of $3.92. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $6.40. The firm has a market capitalization of $123.30 million, a P/E ratio of -1.28 and a beta of 1.74.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.